Management of Antithrombotic Therapy in Post PCI Patient Undergoing Pericardiotomy due to Large Pericardial Effusion : A case report

Dedy Irawan, Sasmojo Widito, Mohammad Saifur Rohman, Cholid Tri Tjahjono


Background : Stent thrombosis is a serious complication following percutaneous coronary intervention (PCI), and dual antiplatelet therapy (DAPT) is necessary to avoid it. Surgery, on the other hand, is a common cause for stopping DAPT. Because patients were exposed to the possibility of a major adverse cardiovascular event (MACE) when DAPT was stopped, this circumstance poses a clinical dilemma.

Objective : This case report aimed to describe the management of antithrombotic therapy in post PCI patient requiring DAPT who underwent pericardiostomy.
Case : A 69-year-old woman with large pericardial effusion without cardiac tamponade, breast cancer on chemo- therapy, heart failure stage C NYHA functional class II, chronic coronary syndrome post-DES implantation at proximal-mid LAD, and hypertension. The patient underwent pericardiotomy procedures five days after DAPT discontinuation. For the bridging therapy, continuous UFH administration was initiated at a dose of 18 IU/kg/hour after the cessation of DAPT. The UFH dose was adjusted to achieve activated partial thromboplastin time (APTT) 1.5 to 2.0 times the control value. The UFH was discontinued 6 hours before surgery. After surgery, UFH infusion was restarted 6 hours after the confirmation of hemostasis. The administration of UFH then continued until three days after DAPT was restarted. No complications were found during and after the pericar- diostomy.

Conclusion : We reported an antithrombotic treatment strategy in a post PCI patient undergoing pericardiostomy with discontinuation of DAPT, which was successfully treated with UFH without any complication. The UFH has been widely used in perioperative settings as a bridging therapy during the interruption of DAPT and may be considered in this condition.



Antithrombotic therapy; Prcutaneous Coronary Intervention; Pericardiostomy; Pericardial Effusion.

Full Text:



Banerjee S, Angiolillo DJ, Boden W, et al. Use of antiplatelet therapy/DAPT for post PCI Patients Undergoing Noncardiac Surgery. JACC. 2017;1861-70.

Van Diepen S, Tricoci P, Podder M, et al. Efficacy and safety of vorapaxar in non-ST-segment elevation acute coronary syndrome patients undergoing noncardiac surgery. J Am Heart Assoc 2015;4:e002546.

Rossini R, Musumeci G, Visconti LO, et al. Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention 2014;10:38–46.

Rossini R, Tarantini G, Musumeci G, et al. A Multidisiplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery. Surgery After Stenting 2. JACC. Cardiovasc Interv 2018;417–34.

Watson RD, Chin BS, Lip GY. Antithrombotic therapy in acute coronary syndromes. Clinical review. BMJ. 2002;325:1348-51.

Claessen BE, Henriques JP, Jaffer FA, et al. Stent thrombosis : A clinical perspective. JACC : Cardiovascular interventions 2014;1081-92.

Hawn MT, Graham LA, Richman JS, et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA 2013;310:1462–72.

Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000;35:1288–94.

Abualsaud AO, Eisenberg MJ. Perioperative Management of Patients With Drug-Eluting Stents. JACC : Cardiovascular interventions 2010;131-42.

Tanaka A, Ishii H, Tatami Y, et al. Unfractionated Heparin during the Interruption of Antiplatelet Therapy for Non-cardiac Surgery after Drug-eluting Stent Implantation. Intern Med 2016;55: 333-337.

Blann D, Landray MJ, Lip GY. An overview of antithrombotic therapy. Clinical review. BMJ. 2002;325:762-65.

Neumann FJ, Uva MS, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal 2018; 00:1–96.

Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal. 2017; 0, 1–48

Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082–115.

Egholm G, Kristensen SD, Thim T, et al. Risk associated with surgery within 12 months after coronary drug-eluting stent implantation. J Am Coll Cardiol 2016;68:2622–32.

Mahmoud KD, Sanon S, Habermann EB, et al. Perioperative cardiovascular risk of prior coronary stent implantation among patients undergoing noncardiac surgery. J Am Coll Cardiol 2016;67: 1038–49.

Angiolillo DJ, Firstenberg MS, Price MJ, et al., BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307:265–74.

Morici N, Moja L, Rosato V, Sacco A, Mafrici A, Klugmann S, et al. Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review. Intern Emerg Med 2014; 9: 225-35

Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery: a prospective outcome study. Br J Anaesth 96: 686-693, 2006.



  • There are currently no refbacks.

Copyright (c) 2021 dedy irawan, sasmojo widito

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.